Endobronchial metastasis is defined as nonpulmonary neoplasms that metastasize to the proximal central or subsegmental bronchus, in a bronchoscopically visible range, and is frequently associated with primary tumors of the kidney, colon/rectum, breast, and others (2). To the best of our knowledge, there have been no previous reports of endobronchial metastasis from gastrinoma. This is the first reported case of endobronchial metastasis from gastrinoma. Therefore, the present case reminds physicians to consider endobronchial metastasis from extrathoracic endocrine neoplasms.Therapy for gastrinoma includes surgery for localized disease, debulking surgery for metastatic disease, and chemotherapy. More than sixty percent of gastrinomas are malignant; 5-year survival for patients with gastrinoma with liver metastases is between 40% and 75%, and it is almost 100% when no liver metastases are present (3). In this patient, tumor progression has been slow, and he remains almost asymptomatic after debulking surgery for liver metastases and chemotherapy. 2007-2008 (2). A meta-analysis of prospective studies showed a dose-dependent relationship between increasing body mass index (BMI) and the risk of incident asthma (3). Understanding the influence of BMI and obesity on effectiveness of interventions to improve asthma control will help clinicians better care for obese patients with asthma. The Better Outcomes of Asthma Treatment study, a randomized controlled trial in 612 adults with poorly controlled asthma, found that a shared treatment decision-making (SDM) intervention improved controller medication adherence and clinical outcomes (4). Given the increased attention to the links between obesity and asthma, we conducted post hoc analyses to investigate whether baseline BMI modified the SDM intervention effects on asthma medication acquisition outcomes (fill/ refill adherence and regimen strength) and clinical outcomes in the follow-up year. We hypothesized that obese patients would have benefitted less from the SDM intervention than did overweight or normal weight patients. Some of the results reported here were previously reported in the form of an abstract (5).Standard BMI categories were defined: normal (18.5-24.9 kg/m 2 , n ¼ 132) and underweight (,18.5 kg/m 2 , n ¼ 7) combined, overweight (25-29.9 kg/m 2 , n ¼ 185), and obese ($30 kg/m 2 , n ¼ 286). Using comprehensive pharmacy dispensing records, we computed continuous medication acquisition (CMA) indices (6-8) to measure fill/refill adherence for controller medications (inhaled corticosteroids, leukotriene modifiers, and others) and for long-acting b agonists (LABA) during the 12 months before and after randomization of individual participants. Controller and LABA medication regimen strength was measured by cumulative beclomethasone canister-equivalents (C-E) and salmeterol diskus-equivalents (D-E), respectively, using a standardized weighting methodology (9). Clinical outcome measures included the symptom subscale of the Juniper mini-Asthma Quality of Life Questi...